Allergy Therapeutics – argues “significant clinical progress”, so why the further share price fall?
Allergy Therapeutics (AGY) has issued a trading update for its year ended 30th June 2022 emphasising “effective cost controls implemented alongside the group's significant clinical progress” and “in 2023, sales are expected to return to their previous near double-digit growth levels”. So what of a current share price response to 17p, approaching 7% lower?
- By Steve Moore
- 2022-07-15 16:05:53